Research article

Susceptibility to collagen-induced arthritis is modulated by TGFβ responsiveness of T cells

Christoph Schramm1, Jörg Kriegsmann2, Martina Protschka3, Samuel Huber1, Torsten Hansen4, Edgar Schmitt5, Peter Robert Galle1 and Manfred Blessing2,6

1I. Medizinische Klinik, Johannes Gutenberg-Universität Mainz, Mainz, Germany
2Gemeinschaftspraxis für Pathologie, Trier, Germany
3I. Medizinische Klinik, Abteilung Pathophysiologie, Johannes Gutenberg-Universität Mainz, Mainz, Germany
4Institut für Pathologie, Johannes Gutenberg-Universität Mainz, Mainz, Germany
5Institut für Immunologie, Mainz, Germany
6Biotechnologisch-Biomedizinisches Zentrum, Leipzig, Germany

Correspondence: Christoph Schramm (e-mail: schramm@uni-mainz.de)

Received: 7 Nov 2002 Revisions requested: 29 Nov 2002 Revisions received: 12 Dec 2003 Accepted: 17 Dec 2003 Published: 8 January 2004

Arthritis Res Ther 2004, 6:R114-R119 (DOI 10.1186/ar1039)
© 2004 Schramm et al., licensee BioMed Central Ltd (Print ISSN 1478-6354; Online ISSN 1478-6362). This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article’s original URL.

Abstract

The objective of our study was to determine the regulatory effects that endogenous transforming growth factor β (TGFβ) exerts on T cells in the pathogenesis of collagen-induced arthritis (CIA). CIA was induced in transgenic mice expressing a dominant negative TGFβ type II receptor in T cells under the control of the human CD2 promoter. Clinical and histological arthritis scores were determined and experiments on disease induction and the healing phase of disease were performed. The proliferation and cytokine production of draining lymph node cells in vitro were analyzed. Transgenic mice were more susceptible to induction of CIA. The overall incidence was higher in transgenic mice than in wild-type mice (57% vs 35%, P<0.05). Affected transgenic animals displayed a significantly higher clinical (4.5±0.6 vs 1.67±0.19, P=0.001) and histological arthritis score (8.01±0.9 vs 4.06±1.1, P<0.05). Draining lymph node cells of transgenic mice secreted more tumor necrosis factor α and IFNγ and proliferated more vigorously in response to collagen type II and upon CD3/CD28 costimulation in vitro. Therefore, the regulation of T cells by endogenous TGFβ is important for the maintenance of joint integrity after arthritis induction. Defects in TGFβ-signalling as a susceptibility factor for rheumatoid arthritis may warrant further investigation.

Keywords: dominant negative TGFβ type II receptor, IFNγ, transgenic mice

Introduction

Collagen-induced arthritis (CIA) is an experimental model sharing several clinical and pathological features with rheumatoid arthritis (RA). CIA has been used to study the pathogenesis of RA [1]. The importance of T cells in the pathogenesis of CIA and RA has been established [2] and numerous studies have been performed to determine the cytokines and susceptibility factors involved in arthritis development [3]. However, little is known about the regulation of T cells that leads to the maintenance of immune homeostasis within the joint.

Transfoming growth factor beta (TGFβ) family members are pleiotropic factors produced by a variety of cells and with actions depending on the context of their production [4]. Besides having effects on cell proliferation and differentiation and on matrix regulation and tissue repair, TGFβ1 is a major immunoregulatory factor [4]. TGFβ has been detected in RA synovial tissue, and suppressive effects of synovial fluid have been attributed to its actions [5]. In line with its site- and context-specific action, conflicting results have emerged from the use of exogenous TGFβ1 systemically or locally in joints and from the use of...
anti-TGFβ antibodies. The systemic administration of TGFβ to mice ameliorated CIA [6], whereas its local administration to foot pads and joints in rats induced synovitis and aggravated their disease [4,7]. Similarly, blocking endogenous TGFβ by the systemic injection of anti-TGFβ antibody aggravated CIA in mice [6], whereas it ameliorated the ongoing inflammation when injected into the joints of rats [8]. TGFβ also has important functions in tissue repair and fibrosis and chondrocyte differentiation [9]. These conflicting results underline the need for a better understanding of the role of endogenous TGFβ in the maintenance of joint integrity.

The immunoregulatory effects of TGFβ have been clearly demonstrated in TGFβ-null mice, which die by four weeks of age because of multifocal inflammatory lesions, mainly in the lung and heart [10]. No joint lesions have been reported in these mice, but probably their life span was too short for the development of arthritis. In addition, it is difficult to delineate the effects of TGFβ to a specific cell type in this model. We have therefore used transgenic FVB/N mice with an impaired TGFβ-signalling pathway in T cells to delineate the regulatory effects of TGFβ on T cells in the maintenance of joint homeostasis in CIA [11]. The transgenic mice express a dominant negative TGFβ type II receptor under the control of the human CD2 promoter in T cells. This receptor lacks the intracellular kinase domain that is responsible for the phosphorylation of the type I receptor and the subsequent activation of the signalling cascade [12]. The truncated receptor competes with the endogenous type II receptor on the cell surface, thereby blocking TGFβ signal transduction.

We found a higher incidence of CIA in transgenic mice and a higher clinical and histological arthritis score with an increased production of Th1 cytokines by draining lymph node cells of transgenic mice. These findings indicate the importance of regulatory effects of endogenous TGFβ on T cells in the maintenance of joint integrity.

**Materials and methods**

**Animals**

The generation and characterization of transgenic hCD2-ΔkTβRII mice is described elsewhere [11]. In these mice, impaired TGFβ-signalling in T cells was shown to be similar to that in other models reported [13,14]. All transgenic lines were established and maintained as heterozygotes on an FVB/N background. FVB/N mice are naturally resistant to the induction of CIA [15]. Therefore, hCD2-ΔkTβRII mice were crossed with DBA/1 mice (Charles River, Sulzfeld, Germany). The male F1 generation was genotyped using PCR as described elsewhere [11] and included in the experiments at 6 to 12 weeks of age. Nontransgenic male littermates were used as controls. In four separate experiments, 49 transgenic and 29 wild-type F1 mice were included in the analysis of acute arthritis. An additional 14 transgenic and 17 wild-type mice were included in the analysis of the chronic phase of disease. Animal care was in accordance with governmental and institutional guidelines.

**Induction of CIA**

Chicken collagen type II (CII) (Sigma, Deisenhofen, Germany) was dissolved and stored in 0.01 M acetic acid at 4 mg/ml. Wild-type and transgenic F1 mice were injected intradermally with 100 µg of CII emulsified in complete Freund’s adjuvant (charge H37Ra) (Difco, Detroit, MI, USA) in both ears (25 µg each) and the base of the tail (50 µg). A booster injection of 100 µg CII in 100 µl PBS was given intraperitoneally 21 days later. Arthritis usually developed within the first week after the booster injection.

**Clinical arthritis scoring**

Mice were scored every two to three days in the acute phase and once a week in the chronic phase of arthritis, and grades ranging from 0 to 4 were allotted to each limb: grade 0, no visible abnormalities; grade 1, mild redness or swelling of wrist or up to three inflamed digits; grade 2, more than three inflamed digits or moderate redness and swelling of ankle or wrist; grade 3, severe ankle and wrist inflammation; grade 4, extensive ankle and wrist inflammation including all digits, or new bone formation with reduced motion. A maximum score of 16 could be achieved for each mouse.

**Histological assessment**

For the analysis of acute arthritis, anesthetized mice were killed by cervical dislocation when no further clinical deterioration occurred, which was within the first six weeks after the onset of arthritis. For the analysis of the healing phase of arthritis, mice were observed up to 24 weeks after arthritis induction. After removal of draining lymph nodes, all four limbs of mice with a clinical arthritis score of at least grade 1 were removed. Specimens were fixed in formalin and decalcified in 10% Tris-buffered EDTA (pH 7.3) for 24 to 72 hours using standard methods. Sections 5 µm thick were cut and stained with hematoxylin and eosin.

The histological arthritis score was determined in a blinded fashion for inflammatory and degenerative changes and graded from 0 and 3 for each limb as follows:

**Synovial lining** – grade 0, no changes; grade 1, localized monolayer cubical transformation; grade 2, localized multilayer cubical transformation; grade 3, multilayer synovial lining with extensive necrosis

**Cellular infiltrate** – grade 0, no changes; grade 1, few focal infiltrates; grade 2, extensive focal infiltrates; grade 3, extensive infiltrates invading the capsule with aggregate formation

**Cartilage** – grade 0, no changes; grade 1, superficial, localized cartilage degradation in more than one region;
grade 2, localized deep cartilage degradation; grade 3, extensive deep cartilage degradation at several locations. Pannus – grade 0, no changes; grade 1, pannus formation at up to two sites; grade 2, pannus formation at up to four sites, with infiltration or flat overgrowth of joint surface; grade 3, pannus formation at more than four sites or extensive pannus formation at two sites.

Of the four limbs analyzed per animal, the maximum score for each category was used. Therefore, a maximum score of 12 could be reached per animal.

**Cell culture and cell proliferation assay**

Popliteal and axillary draining lymph nodes were removed and ground through a 40-µm nylon mesh. Cells were cultivated in RPMI 1640 medium (Biochrom, Berlin, Germany) containing 5% fetal calf serum supplemented with penicillin (100 U/ml) and streptomycin (100 µg/ml) (Life Technologies, Eggenstein, Germany). 2 × 10⁶ cells/ml were plated and incubated with 50 µg/ml of CII or costimulated with anti-CD3/CD28 antibodies at 37°C in a water-saturated atmosphere with 5% CO₂ in air. For costimulation, plates were precoated with 10 µg/ml antimouse CD3 monoclonal antibodies (BD Pharmingen, Heidelberg, Germany) in 0.1 M sodium phosphate buffer, pH 8.5, overnight at 4°C, and 10 µg/ml antimouse CD28 monoclonal antibodies (BD Pharmingen) was then added to the medium. Supernatants were collected after 48 hours and frozen in liquid nitrogen. For proliferation assays, cells were seeded at 5 × 10⁵ cells per well in 96-well flat-bottomed plates (Greiner Bio-One, Frickenhausen, Germany) in RPMI medium. Cells were incubated for 48 hours and pulsed with 0.25 µCi/well [³H]-thymidine (37 MBq/ml) for the last 16 hours of culture. Samples were harvested and counted in a Betaplate liquid scintillation counter (Wallac, Freiburg, Germany).

**ELISA**

Cytokine levels of IL-2, IL-4, IL-5, IL-6, IL-10, tumor necrosis factor α (TNFα), and IFNγ in supernatants were measured using Mouse BD OptEIA ELISA Sets (BD Pharmingen) in accordance with the manufacturer’s instructions.

**Statistical analysis**

Means ± SEM are given. For comparison of groups, the two-sided Mann–Whitney rank sum test was applied. A value of *P* < 0.05 was considered significant.

**Results**

**Clinical and histological severity of arthritis**

Mice with signs of inflammation at any time point during the observation period were included in the analysis of the severity of arthritis. In four separate experiments analysing the acute phase of arthritis, the overall arthritis incidence in transgenic mice was 57% (28/49), compared with only 35% (12/34) in wild-type littermates (*P* < 0.05). Arthritis usually developed within the first 10 days after the booster injection of CII and lasted for at least four weeks, when a steady state was reached and the mice were killed. The clinical arthritis score was significantly higher in transgenic than in wild-type mice (4.5 ± 0.6 vs 1.67 ± 0.19, *P* = 0.001; Fig. 1b). No significant joint inflammation was observed in wild-type or transgenic FVB/N mice (data not shown). In long-term experiments analysing the healing phase of the disease, a plateau of disease activity in transgenic F₂ mice was reached after the initial flare had subsided after about 12 weeks. Therefore, chronic arthritis developed, which remained stable over the next 10–12 weeks without a tendency to heal. Only minor changes in disease activity were observed in wild-type mice. The time course of arthritis development for one representative long-term experiment out of two is shown in Fig. 1a.

The histological arthritis score was determined in all limbs of mice with a clinical score of at least grade 1 during the observation period. Inflammatory and degenerative changes were more severe in mice with impaired TGFβ-signalling in T cells. The time course of the severity of arthritis after the booster injection (day 0) of one long-term experiment is shown. This experiment involved six wild-type and eight transgenic mice. Means ± SEM are shown. (b) The maximum clinical arthritis score of mice with a clinical score of at least grade 1 during the observation period of four separate short-term experiments was significantly higher in transgenic mice than in wild-type mice (mean ± SEM; **P** = 0.001). (c) Mice with a clinical score of at least grade 1 were analyzed histologically for inflammatory and degenerative changes. Transgenic mice had significantly higher histological scores than wild-type mice (mean ± SEM; *P* < 0.05). TG, tg, transgenic; WT, wt, wild-type.
Increased inflammatory and degenerative changes in transgenic hCD2-ΔkTβRII mice after the induction of CIA. Representative sagittal histological sections stained with hematoxylin and eosin are shown. (a–c) A small joint of the extremities (a) of a wild-type mouse, and a larger joint (b), show a smooth cartilage surface without any cartilage or bone destruction. (c) The synovial lining layer is composed of flat synovial cells or is mildly hyperplastic. (d–f) Joints of transgenic mice with severe inflammatory changes also affecting the periarticular soft tissue are shown. (d) Destruction was seen in small joints, with fibroproliferative tissue (lower portion) and numerous neutrophils within the articular space (upper portion and f). Bone destruction has resulted in bone modulation. (e) In larger joints of the extremities, also, there is heavy proliferation of fibrocellular tissue (pannus formation) with joint destruction. Scale bars represent 100 μm.

Discussion

Our results demonstrate the importance of endogenous TGFβ in regulating T cells in order to maintain joint integrity in vivo. Results of studies of the role of endogenous TGFβ in the development of joint lesions have been contradictory [6,8]. TGFβ is a pleiotropic cytokine, produced by a variety of cells and known to exert its effects depending on the effector cell and the context of production [4].

TGFβ has been detected in the synovium and effusions of arthritic joints, and an immunosuppressive role has been postulated from results of in vitro experiments [5]. The importance of TGFβ in maintaining immune homeostasis has been demonstrated in TGFβ knockout mice, which die within the first weeks of life as a result of multifocal inflammatory lesions, especially in the heart and lungs [10]. Because it is difficult to delineate the effects of the lack of TGFβ on a specific cell type in these mice, various methods have been used to impair TGFβ-signalling in specific cell types using cell-specific promoters. A dominant negative TGFβ type II receptor has been overexpressed in T cells using the CD4 and the CD2 promoter [13,14]. In addition, Smad7, an inhibitory Smad protein, has been expressed in T cells [16]. The phenotypes of these transgenic mice have turned out to be different from each other, probably because of strain differences and as yet unknown mechanisms.

Although T cells have been shown in several models to be important for the development of arthritis [2], in none of these mice has the spontaneous development of arthritis been described, indicating a tight regulation of immune homeostasis within the joint. The transgenic mice used in this study did not develop spontaneous arthritis even after an observation period of more than nine months [11]. Moreover, hCD2-ΔkTβRII mice developed only minimal
Inflammatory lesions on distal joints after immunization with CII. These mice were generated on an FVB/N background. FVB/N mice have been reported to be resistant to CIA, although they express the same MHC haplotype as DBA/1 mice, a major susceptibility factor for the development of CIA. Still, antigen recognition might be impaired in FVB/N mice due to deletions in the T-cell receptor Vβ genes [15]. Therefore, the F₁ generation of transgenic mice expressing a dominant negative TGFβ receptor under the control of a metallothionein-like promoter has resulted in degenerative changes and bone malformation, the changes in joints resembling those seen in osteoarthritis [9]. TGFβ therefore seems to have beneficial effects in the promotion of tissue repair and down-regulation of inflammation, but when these regulatory effects are not sufficient to control disease, negative effects such as fibrosis and bone remodelling could predominate in the long term.

Conclusion

A significantly higher incidence and severity of CIA were observed in transgenic mice with impaired TGFβ-signalling than in wild-type littermates. These results demonstrate that endogenous TGFβ acts on T cells to maintain joint integrity after the induction of arthritis and during the healing phase of disease. Several studies have been performed on the susceptibility factors contributing to the development of arthritis. Our data suggest assessment of the TGFβ-signalling cascade as an as yet unknown susceptibility factor.

Competing interests

None declared.
Acknowledgements
This work was supported by the DFG, SFB 548 and MAIFOR, Faculty of Medicine, University of Mainz. The authors thank Marina Smetkova for excellent technical assistance.

References
1. Anthony DD, Haqqi TM: Collagen-induced arthritis in mice: an animal model to study the pathogenesis of rheumatoid arthritis. Clin Exp Rheumatol 1999, 17:240-244.
2. Taneja V, Taneja N, Paisesinsap T, Behrens M, Griffiths M, Luthra H, David CS: CD4 and CD8 T cells in susceptibility/protection to collagen-induced arthritis in HLA-DQ8-transgenic mice: implications for rheumatoid arthritis. J Immunol 2002, 168:5867-5875.
3. Feldmann M, Brennan FM, Maini RN: Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996, 14:397-440.
4. Letterio JJ, Roberts AB: Regulation of immune responses by TGF-beta. Annu Rev Immunol 1998, 16:137-161.
5. Lotz M, Kekow J, Carson DA: Transforming growth factor-beta and cellular immune responses in synovial fluids. J Immunol 1990, 144:4189-4194.
6. Thorbecke GJ, Shah R, Leu CH, Kuruvilla AP, Hardison AM, Paladino MA: Involvement of endogenous tumor necrosis factor alpha and transforming growth factor beta during induction of collagen type II arthritis in mice. Proc Natl Acad Sci USA 1992, 89:7375-7379.
7. Allen JB, Manthey CL, Hand AR, Ohura K, Ellingsworth L, Wahl SM: Rapid onset synovial inflammation and hyperplasia induced by transforming growth factor beta. J Exp Med 1990, 171:231-247.
8. Wahl SM, Allen JB, Costa GL, Wong HL, Dasch JR: Reversal of acute and chronic synovial inflammation by anti-transforming growth factor beta. J Exp Med 1993, 177:225-230.
9. Serra R, Johnson M, Filvaroff EH, LaBorde J, Sheehan DM, Derynck R, Moses HL: Expression of a truncated, kinase-defective TGF-beta type II receptor in mouse skeletal tissue: promotes terminal chondrocyte differentiation and osteoarthritis. J Cell Biol 1997, 139:541-552.
10. Kulkarni AB, Huh CG, Becker D, Geiser A, Lyght M, Flanders KC, Roberts AB, Sporn MB, Ward JM, Karlsson S: Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci USA 1993, 90:770-774.
11. Schramm C, Prottschka M, Köhler H, Podlech J, Reddahase MJ, Schrack C, Galle PR, Lohse AW, Blessing M: Impairment of TGF-beta signaling in T-cells increases susceptibility to experimental autoimmune hepatitis in mice. Am J Physiol 2003, 284:G525-G535.
12. Brand T, MacLellan WR, Schneider MD: A dominant-negative receptor for type beta transforming growth factors created by deletion of the kinase domain. J Biol Chem 1993, 268:11500-11503.
13. Gorelik L, Flavell RA: Abrogation of TGFbeta signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. Immunity 2000, 12:171-181.
14. Lucas PJ, Kim SJ, Melby SJ, Gress RE: Disruption of T cell homeostasis in mice expressing a T cell-specific dominant negative transforming growth factor beta II receptor. J Exp Med 2000, 191:1187-1196.
15. Osman GE, Hannibal MC, Anderson JP, Lasky SR, Ladiges WC, Hood L: FVB/N (H2(q)) mouse is resistant to arthritis induction and exhibits a genomic deletion of T-cell receptor V beta gene segments. Immunogenetics 1999, 49:851-859.
16. Nakao A, Mike S, Hatano M, Okumura K, Tokuhisa T, Ra C, lwamoto I: Blockade of transforming growth factor beta/Smad signaling in T cells by overexpression of Smad7 enhances antigen-induced airway inflammation and airway reactivity. J Exp Med 2000, 192:151-158.

Correspondence
Dr Christoph Schramm, I. Department of Medicine, Johannes Gutenberg-University, Langenbeckstr. 1, 55101 Mainz, Germany; Tel: +49 6131 393359; fax: +49 6131 393396; e-mail: schramm@uni-mainz.de